目的 探討安胃瘍膠囊聯(lián)合硫糖鋁混懸凝膠治療胃潰瘍的臨床療效。方法 選取2021年8月—2023年6月巴中市中心醫(yī)院收治的166例胃潰瘍患者，按照隨機(jī)數(shù)字表法分為對照組和治療組，每組各83例。對照組給予硫糖鋁混懸凝膠，1 g/次，晨起飯前1 h、睡前空腹各服用1次。治療組在對照組治療基礎(chǔ)上口服安胃瘍膠囊，2粒/次，4次/d，3餐后和睡前口服，溫開水送服。兩組療程6周。觀察兩組的臨床療效，比較兩組治療前后典型癥狀評分，統(tǒng)計潰瘍愈合率、幽門螺桿菌（Hp）根除率，并比較治療前后兩組36項(xiàng)健康調(diào)查簡表（SF-36）、癥狀自評量表（SCL-90）評分及血清胃功能指標(biāo)[胃蛋白酶原Ⅰ（PGⅠ）、PGⅠ與胃蛋白酶原Ⅱ比值（PGR）、胃泌素-17（G-17）]和前列腺素E₂（PGE₂）水平。結(jié)果 治療后，治療組總有效率是96.39%，顯著高于對照組的87.95%（P＜0.05）。治療后，兩組患者上腹痛評分、噯氣評分、反酸評分均顯著降低（P＜0.05）；治療后，治療組典型癥狀評分低于對照組（P＜0.05）。治療后，治療組潰瘍愈合率、Hp根除率分別是75.90%、90.36%，顯著高于對照組的（61.45%、78.31%）（P＜0.05）。治療后，兩組SF-36評分顯著升高，而SCL-90評分顯著降低（P＜0.05）；治療后，治療組SF-36評分和SCL-90評分改善優(yōu)于對照組（P＜0.05）。治療后，兩組PGI、PGR、G-17低于同組治療前，而血清PGE₂水平高于同組治療前（P＜0.05）；治療后，治療組血清胃功能指標(biāo)和PGE₂水平改善優(yōu)于對照組（P＜0.05）。結(jié)論 安胃瘍膠囊聯(lián)合硫糖鋁混懸凝膠治療胃潰瘍具有較好的臨床療效，能有效促進(jìn)Hp根除和癥狀緩解，改善胃黏膜功能，利于潰瘍愈合及患者身心狀態(tài)恢復(fù)。

Objective To investigate the clinical efficacy of Anweiyang Capsules combined with Sucralfate Suspensoid Gel in treatment of gastric ulcer. Methods A total of 166 patients with gastric ulcer admitted to Bazhong Central Hospital from August 2021 to June 2023 were selected and divided into control group and treatment group according to random number table method, with 83 cases in each group. Patients in the control group were given Sucralfate Suspensoid Gel, 1 g/time, 1 time in the morning 1 h before meals and 1 time on an empty stomach before going to bed. Patients in the treatment group were po administered with Anweiyang Capsules on the basis of the control group, 2 capsules/time, 4 times daily, after three meals and before going to bed, with warm water. Both groups were treated for 6 weeks. The clinical efficacy of the two groups was observed, the typical symptom scores of the two groups were compared before and after treatment, and the ulcer healing rate and Helicobacter pylori (Hp) eradication rate were analyzed. The scores of 36 health survey Summary Form (SF-36), Symptom Checklist (SCL-90) and serum gastric function indexes [pepsinogen Ⅰ (Pⅰ), ratio of Pⅰ to pepsinogen Ⅱ (PGR), gastrin-17 (G-17)] and prostaglandin E2 (PGE2) before and after treatment were compared between two groups. Results After treatment, the total effective rate of the treatment group was 96.39%, which was significantly higher than that of the control group (87.95%, P < 0.05). After treatment, the scores of upper abdominal pain, belching and acid reflux in 2 groups were significantly decreased (P < 0.05). After treatment, the typical symptom score of treatment group was lower than that of the control group (P < 0.05). After treatment, the ulcer healing rate and Hp eradication rate in treatment group were 75.90% and 90.36%, respectively, which were significantly higher than those in control group (61.45% and 78.31%) (P < 0.05). After treatment, SF-36 score was significantly increased in both groups, but SCL-90 score was significantly decreased (P < 0.05). After treatment, the improvement of SF-36 score and SCL-90 score in treatment group was better than that in control group (P < 0.05). After treatment, PGI, PGR and G-17 in two groups were lower than before, while serum PGE₂ level was higher than before (P < 0.05). After treatment, the improvement of serum gastric function index and PGE₂ level in treatment group was better than that in control group (P < 0.05). Conclusion Anweiyang capsule combined with sucralfate suspension gel has good clinical effect in treatment of gastric ulcer, and can effectively promote the eradication of Hp and relieve symptoms, improve the function of gastric mucosa, which can facilitate ulcer healing and physical and mental recovery of patients.

R975